The growth inhibitory activity of the Cimicifuga racemosa extract Ze 450 is mediated through estrogen and progesterone receptors-independent pathways.
Despite the wide use of Cimicifuga racemosa (CR) extract to treat symptoms associated with menopause and other gynecological disorders, very little is known about its mechanism of action. Therefore, we studied in this report the antiestrogenic and antiproliferative effect of a new CR ethanolic extract, Ze 450, in a MCF-7 cell clone that does not proliferate in response to 17beta-estradiol (E(2)). Using this cell line, we have found that the extract inhibited cell proliferation and showed antiestrogenic activity using an ERE-luciferase reporter assay. The growth inhibitory activity was different from the antiestrogenic activity since the CR extract also inhibited the growth of the ER-negative human breast cancer cell line T-47D. Also, we evaluated the effects of this CR extract on the transcriptional regulation of genes involved in cell cycle progression in the ER-negative cell lines 293T and T-47D and we found that this extract markedly inhibited the luciferase activity driven by the cyclin D1 promoter and increased the transcriptional activity of the p21 gene promoter. Finally, we observed that our CR extract bound to the progesterone receptor B1 but did not show progestin-like activity in the T-47D cell line. These findings provide new mechanistic insights into the antiproliferative activities of CR in ER-positive and ER-negative tumour cell lines and highlight their potential in the management of climacteric disorders in women with a history of breast cancer.
Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Córdoba, Spain.
Marcela
M
Garita-Hernandez
Marco A
MA
Calzado
Francisco J
FJ
Caballero
Antonio
A
Macho
Eduardo
E
Muñoz
Beat
B
Meier
Axel
A
Brattström
Bernd L
BL
Fiebich
Kurt
K
Appel
D001943:Breast Neoplasms; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured / Q000187:drug effects; D031885:Cimicifuga; D004305:Dose-Response Relationship, Drug; D004958:Estradiol; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D019584:Hot Flashes / Q000188:drug therapy; D006801:Humans; D008593:Menopause; D009376:Neoplasms, Hormone-Dependent; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011960:Receptors, Estrogen / Q000187:drug effects*; D011980:Receptors, Progesterone / Q000187:drug effects*; D027343:Rhizome
D004965:Estrogen Antagonists; D010936:Plant Extracts; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C510722:Ze 450; D004958:Estradiol